Policy | October 12, 2025
AstraZeneca to lower cost of medicines for American patients
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
New study presents a human-relevant stress model for assessing potential therapeutics
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated
